ES2183516T3 - Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol. - Google Patents

Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol.

Info

Publication number
ES2183516T3
ES2183516T3 ES99906229T ES99906229T ES2183516T3 ES 2183516 T3 ES2183516 T3 ES 2183516T3 ES 99906229 T ES99906229 T ES 99906229T ES 99906229 T ES99906229 T ES 99906229T ES 2183516 T3 ES2183516 T3 ES 2183516T3
Authority
ES
Spain
Prior art keywords
alkyl
aryl
integer
range
independently represent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99906229T
Other languages
English (en)
Inventor
Chuen Chan
Caroline Mary Cook
Brian Cox
Richard Peter Cousins
Hazel Joan Dyke
Frank Ellis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26313119&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2183516(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9803169.3A external-priority patent/GB9803169D0/en
Priority claimed from GBGB9813533.8A external-priority patent/GB9813533D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ES2183516T3 publication Critical patent/ES2183516T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Un compuesto de fórmula (I): en la que R1 y R2 representan independientemente un grupo seleccionado de: (i) cicloalquilo C3-8; (ii) hidrógeno; (iii) aril2CHCH2-; (iv) cicloalquil(C3-8)-alquilo(C1-6); (v) alquilo C1-8; (vi) aril-alquilo(C1-6); (vii) R4R5N-alquilo(C1-6); (viii) alquil(C1-6)-CH(CH2OH)-; (ix) aril-alquil(C1-5)-CH(CH2OH)-; (x) aril-alquil(C1-5)-C(CH2OH)2-; (xi) cicloalquilo C3-8 independientemente sustituido con uno o más grupos -(CH2)pR6; (xii) H2NC(=NH)NH-alquilo(C1-6); (xiii) un grupo de fórmula o grupo grupo tal en el que un átomo de carbono metilénico adyacente a X, o ambos si existen, se sustituye por metilo; (xiv) alquilo(C1-6)-OH; (xv) halógenoalquilo C1-8; (xvi) un grupo de fórmula (xvii) arilo; y (xviii) -(CH2)fSO2NHg(alquilo C1-4)2-g o - (CH2)fSO2NHg(aril-alquilo C1-4)2-g; R3 representa metilo, etilo, -CH=CH2, n-propilo, - CH2CH=CH2; -CH=CHCH3, isopropenilo, ciclopropilo, ciclopropenilo, -CH(OH)CH3, -(CH2)qhalógeno, - (CH2)hY(CH2)iH, -COO(CH2)iH, -CON(CH2)mH((CH2)nH), - CO(CH2)oH, o -C((CH2)uH)=NO(CH2)vH; Y representa O, S o N(CH2)jH; a y b representan independientemente un número entero de 0 a 4, con la condición de que a + b esté en el intervalo de 3 a 5; c, d y e representan independientemente un número entero de 0 a 3, con la condición de que c + d + e esté en el intervalo de 2 a 3; f representa 2 ó 3 y g representa un número entero de 0 a 2; p representa 0 ó 1; q representa 1 ó 2; h representa 1 ó 2, e i representa un número entero de 0 a 1; de forma que h + i esté en el intervalo 1 a 2; j representa un número entero de 0 a 1, tal que h + i + j esté en el intervalo de 1 a 2; l representa 1 ó 2; m y n representan independientemente un número entero de 0 a 2, de forma que que m + n esté en el intervalo de 0 a 2; o representa un número entero de 0 a 2; u y v representan independientemente 0 ó 1, de forma que u + v esté en el intervalo de 0 a 1; R4 y R5 representan independientemente hidrógeno, alquilo C1-6, arilo, aril-alquilo(C1-6) o NR4R5 juntos pueden representar piridinilo, pirrolidinilo, piperidinilo, morfolinilo, azetidinilo, azepinilo, piperazinilo o N-alquil(C1-6)-piperazinilo; R6 representa OH, NH2, NHCOCH3 o halógeno; R7 representa hidrógeno, alquilo C1-6, alquil(C1-6)- arilo, o -CO-alquilo(C1-6); X representa NR7, O, S, SO o SO2; y sus sales y solvatos.
ES99906229T 1998-02-14 1999-02-12 Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol. Expired - Lifetime ES2183516T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9803169.3A GB9803169D0 (en) 1998-02-14 1998-02-14 Chemical compounds
GBGB9813533.8A GB9813533D0 (en) 1998-06-23 1998-06-23 Chemical compounds

Publications (1)

Publication Number Publication Date
ES2183516T3 true ES2183516T3 (es) 2003-03-16

Family

ID=26313119

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99906229T Expired - Lifetime ES2183516T3 (es) 1998-02-14 1999-02-12 Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol.

Country Status (32)

Country Link
US (1) US6610665B1 (es)
EP (1) EP1056759B1 (es)
JP (1) JP2002503669A (es)
KR (1) KR20010082512A (es)
AP (1) AP2000001881A0 (es)
AR (1) AR017457A1 (es)
AT (1) ATE223429T1 (es)
AU (1) AU757156B2 (es)
BR (1) BR9907886A (es)
CA (1) CA2319009A1 (es)
CO (1) CO4990969A1 (es)
DE (1) DE69902758T2 (es)
DK (1) DK1056759T3 (es)
EA (1) EA200000759A1 (es)
EE (1) EE200000358A (es)
ES (1) ES2183516T3 (es)
HK (1) HK1032062A1 (es)
HR (1) HRP20000538A2 (es)
HU (1) HUP0100702A3 (es)
IL (1) IL137402A0 (es)
IS (1) IS5576A (es)
MA (1) MA27121A1 (es)
NO (1) NO20004045D0 (es)
NZ (1) NZ505812A (es)
PE (1) PE20000270A1 (es)
PL (1) PL342396A1 (es)
PT (1) PT1056759E (es)
SK (1) SK12002000A3 (es)
SV (1) SV1999000016A (es)
TR (1) TR200002355T2 (es)
WO (1) WO1999041267A1 (es)
YU (1) YU50800A (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
CO4990969A1 (es) * 1998-02-14 2000-12-26 Glaxo Group Ltd Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol
GB9813565D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
US6495528B1 (en) * 1998-06-23 2002-12-17 Smithkline Beecham Corporation 2-(Purin -9-yl)-tetrahydrofuran-3,4-diol derivatives
GB9813554D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US7427606B2 (en) 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
GB9930075D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
GB0115178D0 (en) * 2001-06-20 2001-08-15 Glaxo Group Ltd Compounds
NZ532062A (en) 2001-10-01 2006-09-29 Univ Virginia 2-propynyl adenosine analogues having A2 adenosine recepter agonist activity and compositions thereof to treat inflammatory responses
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
US6930093B2 (en) * 2003-07-10 2005-08-16 Valeant Research & Development Use of ribofuranose derivatives against inflammatory bowel diseases
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
TWI346109B (en) * 2004-04-30 2011-08-01 Otsuka Pharma Co Ltd 4-amino-5-cyanopyrimidine derivatives
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
US7442687B2 (en) 2004-08-02 2008-10-28 The University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
WO2006015357A2 (en) 2004-08-02 2006-02-09 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
WO2006028618A1 (en) 2004-08-02 2006-03-16 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
AR058104A1 (es) 2005-10-21 2008-01-23 Novartis Ag Compuestos organicos
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
JP2010504933A (ja) 2006-09-29 2010-02-18 ノバルティス アーゲー Ｐｉ３ｋ脂質キナーゼ阻害剤としてのピラゾロピリミジン
EP2089393A1 (en) 2006-10-30 2009-08-19 Novartis AG Heterocyclic compounds as antiinflammatory agents
PL2231642T3 (pl) 2008-01-11 2014-04-30 Novartis Ag Pirymidyny jako inhibitory kinazy
US20110281917A1 (en) 2009-01-29 2011-11-17 Darrin Stuart Substituted Benzimidazoles for the Treatment of Astrocytomas
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
AU2010283806A1 (en) 2009-08-12 2012-03-01 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
SG178454A1 (en) 2009-08-17 2012-03-29 Intellikine Inc Heterocyclic compounds and uses thereof
JP5775871B2 (ja) 2009-08-20 2015-09-09 ノバルティス アーゲー ヘテロ環式オキシム化合物
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
WO2012116217A1 (en) 2011-02-25 2012-08-30 Irm Llc Compounds and compositions as trk inhibitors
JP5957526B2 (ja) 2011-09-15 2016-07-27 ノバルティス アーゲー チロシンキナーゼとしての６−置換３−（キノリン−６−イルチオ）−［１，２，４］トリアゾロ［４，３−ａ］ピラジン
WO2013078440A2 (en) 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
CN110507654A (zh) 2012-04-03 2019-11-29 诺华有限公司 有酪氨酸激酶抑制剂的组合产品和其应用
JP2016512835A (ja) 2013-03-15 2016-05-09 インテリカイン， エルエルシー キナーゼ阻害剤の組み合わせ及びそれらの使用
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
US10195208B2 (en) 2014-07-31 2019-02-05 Novartis Ag Combination therapy
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9414193D0 (en) * 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
TW528755B (en) * 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
CO4990969A1 (es) * 1998-02-14 2000-12-26 Glaxo Group Ltd Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol
US6495528B1 (en) * 1998-06-23 2002-12-17 Smithkline Beecham Corporation 2-(Purin -9-yl)-tetrahydrofuran-3,4-diol derivatives

Also Published As

Publication number Publication date
KR20010082512A (ko) 2001-08-30
EP1056759A1 (en) 2000-12-06
DK1056759T3 (da) 2003-01-06
PE20000270A1 (es) 2000-05-20
PL342396A1 (en) 2001-06-04
HUP0100702A3 (en) 2003-01-28
AP2000001881A0 (en) 2000-09-30
SV1999000016A (es) 1999-10-27
CO4990969A1 (es) 2000-12-26
TR200002355T2 (tr) 2000-11-21
MA27121A1 (fr) 2005-01-03
IS5576A (is) 2000-07-25
HRP20000538A2 (en) 2000-12-31
SK12002000A3 (sk) 2001-07-10
CA2319009A1 (en) 1999-08-19
DE69902758D1 (de) 2002-10-10
NO20004045L (no) 2000-08-11
YU50800A (sh) 2003-04-30
HK1032062A1 (en) 2001-07-06
US6610665B1 (en) 2003-08-26
ATE223429T1 (de) 2002-09-15
JP2002503669A (ja) 2002-02-05
AU757156B2 (en) 2003-02-06
DE69902758T2 (de) 2003-05-15
WO1999041267A1 (en) 1999-08-19
EA200000759A1 (ru) 2001-04-23
EP1056759B1 (en) 2002-09-04
NO20004045D0 (no) 2000-08-11
NZ505812A (en) 2002-03-01
AR017457A1 (es) 2001-09-05
HUP0100702A2 (hu) 2002-01-28
PT1056759E (pt) 2003-01-31
BR9907886A (pt) 2000-10-17
EE200000358A (et) 2001-10-15
IL137402A0 (en) 2001-07-24
AU2623599A (en) 1999-08-30

Similar Documents

Publication Publication Date Title
ES2183516T3 (es) Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol.
ES2186330T3 (es) Derivados de 2-(purina-9-il)-tetrahidrofuran-3,4-diol.
NO905546D0 (no) 11-beta-substituerte progesteronanaloger.
NZ508918A (en) 2-(Purin-9-YL)-tetrahydrofuran-3,4-diol derivatives useful for the treatment of inflammation
HU9303250D0 (en) New perhydroisoindole derivatives, and process for producing them
WO1992014709A3 (en) Calcium channel antagonists and methodology for their identification
FI820281L (fi) Foerfarande foer framstaellning av 2-penemkompositioner med forfarandet framstaellda nya 2-penemkompositioner och dessa inehaollande farmaceutiska blandningar
TW348999B (en) Dihalopropene compounds, insecticidal/acaricidal agents containing same, and intermediates for their production
DE59107712D1 (de) Säurelabile Lösungsinhibitoren und darauf basierende positiv und negativ arbeitende strahlungsempfindliche Zusammensetzung
MY141505A (en) Iodinated aromatic compounds
ES2138623T3 (es) Derivados de pleuromutilina.
DK323179A (da) Polyalkoxyphenylpyrrolidoner iii, fremgangsmaade til deres femstilling og deres anvendelse
FI861672A (fi) Nagellack som innehaoller silyl.
DE3560945D1 (en) Aminoalcohols, process for their preparation and medicaments containing these compounds and intermediates
IE830469L (en) Fungicidal cyanopropenoates
DE59401372D1 (de) Verfahren zur Herstellung von Halogenmethylbenzoylcyaniden und neue Halogenmethyl-benzoylcyanide
DE69016270D1 (de) P-substituierte Propanphosphinsäureverbindungen.
PE6691A1 (es) Tetrahidrobenzopiranopirazoles artropodicidas
ATE90147T1 (de) Atmosphaerischer gasbrenner.
ATE23147T1 (de) Ungesaettigte verbindungen, ihre herstellung und anwendung.
PL339966A1 (en) Novel 1-aza-2-alkyl-6-arylcycloalkane compounds, method of obtaining them and pharmacological compositions containing them
GB1107104A (en) Novel sulphonamides and a process for the manufacture thereof
AR016391A1 (es) Composiciones blanqueadoras liquidas o solidas, metodo para blanquear telas y uso de un catalizador en dicha composicion.
GB2018251A (en) Cyclic acetals
ATE108769T1 (de) Verfahren zur herstellung von phenylsulfonamiden.